Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Vertex Pharmaceuticals announced the U.S. Food and Drug Administration has approved JOURNAVX (suzetrigine) 50 mg oral tablets, a first-in-class, highly…
AbbVie's entry into non-opioid pain via Haisco's NaV1.8 portfolio reflects a strategic pivot following the strong commercial launch of Vertex's Journavx, which…
AbbVie beat Q1 estimates across revenue and EPS, raised full-year guidance. Q1 2026 revenue came in at $15 billion, beating the $14.72 billion consensus and…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AbbVie in-licensed ex-China rights to Haisco's two non-opioid NaV1.8 inhibitors (HSK55718 IV; HSK51155 oral preclinical) for $30M upfront, up to $715M in development/regulatory/commercial milestones, and tiered high single-digit royalties. AbbVie funds R&D through clinical proof of concept; Haisco retains mainland China, Hong Kong and Macau. As of the deal (10 Apr 2026) HSK55718 was in Phase 1; by mid-2026 it had advanced to Phase 2 in China, with two postoperative-pain studies registered (NCT07551739, orthopedic surgery, HSK55718 vs morphine + placebo, Haisco-sponsored; NCT07491146, abdominal surgery, investigator-initiated). Positions AbbVie against Vertex's Journavx (suzetrigine) in the post-opioid acute pain market. Deal remains pending as of June 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Haisco Pharmaceutical Group Co., Ltd. (this deal) | 2026 | $745M | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2026 deals · AbbVie Inc. deals · Other deals